Zealand Pharma A/S (ZEAL)
Copenhagen Exchange · Denmark · prices in DKK · close of 22 Oct 2026
Key indicators
| Last close | DKK 231.40 |
|---|---|
| 52-week range | 220.60 – 556.00 |
| Return, 1 month / 3 months | −17.7% / −21.1% |
| Return, 1 year / 3 years | −49.4% / −22.0% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 71.7% |
| Worst drawdown (1 year) | -59.4% |
| Average daily value traded | 111.22M DKK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Zealand Pharma is a biotechnology company based in Denmark that designs and develops peptide-based medicines. Its work centres on metabolic and gastrointestinal diseases, with products that include a treatment for severe low blood sugar in people with diabetes and a therapy for short bowel syndrome. The company also has earlier-stage programmes in areas such as obesity and other metabolic conditions, and it works with partners on some of its candidates.
The shares are listed on the Copenhagen Exchange in Denmark under the code ZEAL, and the price on this page is in Danish kroner (DKK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Zealand Pharma A/S (ZEAL) trades on the Copenhagen Exchange in Denmark. It last closed at DKK 231.40 on 22 October 2026.
Its price-based Market X-Ray is 21 out of 100 (a weak price profile), ranking 145 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 49.4% and over the last three months it fell 21.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Copenhagen Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 7 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -26.6% | ||
| From 52-week high | -57.6% | ||
| Momentum | 7 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -21.1% | ||
| 6-month return | -24.4% | ||
| 12-month return, skipping the last month | -38.5% | ||
| Stability (higher is calmer) | 8 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 71.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.4% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 111.22M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | −17.7% |
| 3 months | −21.1% |
| 6 months | −24.4% |
| 1 year | −49.4% |
| 3 years | −22.0% |
| 5 years | +11.7% |
Signals
| 50-day / 200-day average | 277.46 / 315.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.78 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Copenhagen Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.